What roulette and basketball can teach Biogen about aducanumab
KELLY DEFINA/GETTY IMAGES
The positive reanalysis of Biogen's EMERGE trial of aducanumab could be a true measure of the drug's benefit. It could just as easily be a false positive.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario